Literature DB >> 8570908

Ischemia reperfusion of the pancreas: a new in vivo model for acute pancreatitis in rats.

T F Hoffmann1, R Leiderer, H Waldner, S Arbogast, K Messmer.   

Abstract

Based on the concept that ischemia is an important factor in the pathogenesis of acute pancreatitis, we developed a new model of complete ischemia/reperfusion of the pancreas in the rat. The aim of this study was to investigate the microcirculation of the pancreas after complete and reversible ischemia at different times after reperfusion by using intravital fluorescence microscopy. In addition, the effect of ischemia/reperfusion on the pancreas was assessed by means of light and electron microscopy and measurement of serum pancreas amylase concentration. In 35 adult Sprague-Dawley rats ischemia of the pancreas was induced by temporary occlusion of the four supplying arteries. Sham-operated animals served as controls (group A). After periods of 30 min (group B), 60 min (group C) or 120 min (group D) of ischemia the organ was reperfused. To exclude the influence of hypovolemia on microcirculation in group E (120 min ischemia) hydroxyethylstarch (HES) was given i.v. to maintain central venous pressure at baseline values. For intravital fluorescence microscopy the pancreas was exteriorized on a stage and quantitative analysis of microcirculation, including functional capillary density and leukocyte-endothelium interaction, was performed after 30 min, 1 h and 2 h of reperfusion. Serum pancreas-amylase was measured at control (prior ischemia) and at 2 h after reperfusion. Tissue samples for light and electron microscopy were taken 2 h after reperfusion. In sham-operated animals, functional capillary density (FCD) remained within baseline values (FCD 407.7 +/- 9 cm-1) during reperfusion. Dependent on the time of ischemia and time of reperfusion a gradual reduction in functional capillary density was observed; after 2 h of ischemia only 35% of capillaries were perfused (FCD 140.9 +/- 28.3 cm-1). Reduced functional capillary density was associated with an increase of perfusion heterogeneity to a maximum of 0.65 +/- 0.12, as against 0.13 +/- 0.02 in control animals. With a 2 h ischemia leukocyte-endothelium interaction was enhanced after 0.5 h of reperfusion (8-fold increase of adherent leukocytes in comparison to control) followed by a further significant increase until 2 h after the beginning of reperfusion. Amylase concentration after ischemia of 2 h (2967 +/- 289 U/l) was significantly higher as compared to controls (1857 +/- 99 U/l). Differences between group E and D were not observed. Pancreatic tissue injury was ascertained by histopathological studies. These results indicate that complete ischemia/reperfusion of the pancreas induces pancreatic microvascular failure. The severity of changes depends on duration of ischemia and duration of reperfusion. The morphological and biochemical changes suggest that ischemia/reperfusion causes an inflammatory reaction as observed in acute pancreatitis.

Entities:  

Mesh:

Year:  1995        PMID: 8570908     DOI: 10.1007/bf02576782

Source DB:  PubMed          Journal:  Res Exp Med (Berl)        ISSN: 0300-9130


  12 in total

Review 1.  Animal Models: Challenges and Opportunities to Determine Optimal Experimental Models of Pancreatitis and Pancreatic Cancer.

Authors:  Jami L Saloman; Kathryn M Albers; Zobeida Cruz-Monserrate; Brian M Davis; Mouad Edderkaoui; Guido Eibl; Ariel Y Epouhe; Jeremy Y Gedeon; Fred S Gorelick; Paul J Grippo; Guy E Groblewski; Sohail Z Husain; Keane K Y Lai; Stephen J Pandol; Aliye Uc; Li Wen; David C Whitcomb
Journal:  Pancreas       Date:  2019-07       Impact factor: 3.327

Review 2.  Resveratrol: a medical drug for acute pancreatitis.

Authors:  Zhen-Hua Ma; Qing-Yong Ma
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

3.  Upregulation of IL-1β, IL-6, and CCL-2 by a novel mouse model of pancreatic ischemia-reperfusion injury.

Authors:  Keri E Lunsford; Brandon J Baird; Gregory D Sempowski; Diana M Cardona; Zhiguo Li; Kent J Weinhold; Debra L Sudan; Todd V Brennan
Journal:  Transplantation       Date:  2013-04-27       Impact factor: 4.939

Review 4.  Animal models of pancreatitis: can it be translated to human pain study?

Authors:  Jing-Bo Zhao; Dong-Hua Liao; Thomas Dahl Nissen
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

Review 5.  Influencing factors of pancreatic microcirculatory impairment in acute panceatitis.

Authors:  Zong-Guang Zhou; You-Dai Chen
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

6.  Pituitary adenylate cyclase activating-peptide and its receptor antagonists in development of acute pancreatitis in rats.

Authors:  You-Dai Chen; Zong-Guang Zhou; Zhao Wang; Hong-Kai Gao; Wen-Wei Yan; Cun Wang; Gao-Ping Zhao; Xiao-Hui Peng
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

7.  Effect of Anti-TNFα Therapy by Infliximab against Pancreatic Tissue Damage in Severe Acute Necrotizing Pancreatitis.

Authors:  S A Alekhin; T I Firsova; D P Nazarenko; E N Bezhina; L V Druzhikin
Journal:  Arch Razi Inst       Date:  2021-11-30

8.  Ischemia-reperfusion rat model of acute pancreatitis: protein carbonyl as a putative early biomarker of pancreatic injury.

Authors:  Alberto Schanaider; Thales Penna de Carvalho; Simone de Oliveira Coelho; Juan Miguel Renteria; Elis Cristina Araújo Eleuthério; Morgana Teixeira Lima Castelo-Branco; Kalil Madi; Wagner Baetas-da-Cruz; Heitor Siffert Pereira de Souza
Journal:  Clin Exp Med       Date:  2014-06-17       Impact factor: 3.984

9.  Review of experimental animal models of acute pancreatitis.

Authors:  Kim Hue Su; Christine Cuthbertson; Christopher Christophi
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

10.  Ischemic preconditioning attenuates capillary no-reflow and leukocyte adherence in postischemic pancreatitis.

Authors:  R Obermaier; E von Dobschuetz; O Drognitz; U T Hopt; S Benz
Journal:  Langenbecks Arch Surg       Date:  2004-01-09       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.